Rituximab side effects range from hours-long infusion reactions to immune changes that can persist for two years or more. The timeline depends entirely on which side effect you’re dealing with. Some resolve within a day, others take months, and a few can linger for years after your last dose.
How Long the Drug Stays in Your Body
Rituximab doesn’t leave your system quickly. After a standard course, the drug has a mean terminal half-life of about 19 days. It remains detectable in the blood for 3 to 6 months after treatment ends. This means your body is still processing the medication long after your last infusion, which is why some side effects emerge or continue well after treatment wraps up.
Infusion-Day Reactions: Hours to Days
The most common side effects are infusion reactions, and they’re usually the shortest-lived. About 32% of patients experience some kind of reaction during or within 24 hours of their first infusion. These typically start 30 to 120 minutes after the infusion begins and can include chills, fever, headaches, rash, nausea, and fatigue. Most resolve once the infusion is slowed or paused.
The first infusion tends to be the worst. Roughly 80% of serious infusion reactions occur with the first dose, and subsequent infusions are generally better tolerated. Here’s what the typical recovery looks like after an infusion:
- During infusion (4 to 6 hours): Fatigue, chills, fever, headache, and nausea are most common in the first few hours.
- First 24 hours: Many people feel wiped out, with muscle aches or a general “crash” feeling that resolves with rest.
- Days 2 through 7: Tiredness, muscle soreness, or mild stomach upset may linger as your body adjusts.
- Beyond one week: Most of these common symptoms gradually fade.
Infection Risk: Highest in the First 3 Months
Rituximab works by depleting a type of immune cell called B cells, which leaves you more vulnerable to infections. The highest-risk window is the first 3 months after treatment. In a registry study of patients with autoimmune kidney diseases, 17.4% developed a serious infection, and the majority of those infections clustered in that early 3-month period.
This vulnerability doesn’t disappear at the 3-month mark. Because B cells take much longer to recover, you remain at somewhat elevated risk for infections for many months. The intensity of that risk simply peaks early and gradually decreases as your immune system rebuilds.
B-Cell Recovery: About 2 Years
This is the side effect with the longest timeline and the one that drives many of the others. Rituximab’s entire purpose is to wipe out B cells, and those cells take a long time to come back. In most patients, B-cell counts return to their pre-treatment levels at a median of about 25 months (roughly 2 years) after the first dose.
That 2-year figure is a median, meaning some people recover faster and some slower. During this entire window, your immune system is operating below its full capacity, which is why infection risk, fatigue, and other immune-related effects can stretch out so long.
Late-Onset Neutropenia: Weeks to Months Later
One of the more surprising side effects is a drop in neutrophils, another type of immune cell, that shows up well after treatment ends. This late-onset neutropenia typically appears about 99 days (roughly 3 months) after the last rituximab dose. It can feel alarming because it seems to come out of nowhere, long after you thought the worst was over.
The good news is that these episodes are usually short. They resolve in a median of 5 days, though some people experience more than one episode.
Low Antibody Levels: Months to Years
Because B cells are responsible for producing antibodies, rituximab can cause antibody levels to drop significantly. This condition, called hypogammaglobulinemia, is one of the longest-lasting potential effects. The median time to develop moderately low antibody levels is about 22.5 months after starting treatment, and severe drops take a median of 24.5 months to appear.
Recovery from low antibody levels is uneven and not guaranteed for everyone. Among patients who developed moderately low levels within the first year, about 45% recovered on their own within 5 years without needing additional treatment. Another 22% required ongoing antibody replacement therapy. The remaining 32% still had low levels at the 5-year mark but managed without replacement therapy. Some individuals do eventually recover normal antibody levels in longer-term follow-up, but for a meaningful percentage, this becomes a lasting concern that requires monitoring.
Putting the Timeline Together
If you’re trying to plan around rituximab side effects, it helps to think of them in three phases. The short-term effects (infusion reactions, fatigue, body aches) are the most noticeable but resolve within a week for most people. The medium-term effects (heightened infection risk, possible neutropenia) span the first 3 to 6 months and require extra vigilance about avoiding illness. The long-term effects (suppressed B cells, potentially low antibody levels) can persist for 2 years or more and are the reason your medical team will likely monitor your blood work for an extended period after your last dose.
The overall pattern is encouraging for most people: the side effects you can feel tend to be short-lived, while the ones that last longer are typically invisible without blood testing. But because your immune system may be quietly compromised for many months, staying aware of signs of infection throughout that recovery window matters more than any single symptom on infusion day.